.jpeg)
2026-05-25 04:05:18
Explore the breakthrough of Sotorasib (AMG-510), the first approved KRAS G12C inhibitor. Detailed clinical trial data, dosage guidelines, and global pricing insights for patients in Hong Kong, Macau, and worldwide.
2026-05-22 04:06:55
LONSURF® (Trifluridine/Tipiracil) has become a cornerstone in the later-line treatment of metastatic colorectal cancer. This article explores its origins at Taiho Pharmaceutical, its unique mechanism of action, and the robust global manufacturing network ensuring its quality and availability.
2026-05-21 06:42:31
Eli Lilly announced FDA approval of Inluriyo (Imlunestrant), an oral estrogen receptor antagonist for ER+, HER2- advanced breast cancer with ESR1 mutations post-endocrine therapy progression.
2026-05-20 02:31:44
Explore the medicinal chemistry and clinical profile of Tivozanib. This guide covers its synthetic route, high selectivity for VEGFR, and role in targeted therapy for advanced kidney cancer.
2026-05-20 02:26:46
A comprehensive guide to Trifluridine/Tipiracil (FTD/TPI), an oral chemotherapy for metastatic colorectal and gastric cancers. Learn about safety profiles, bone marrow suppression, and clinical management strategies.
2026-05-19 07:04:42
This article details the medication precautions and risk management strategies for the KRAS G12C targeted inhibitor Adagrasib in women of childbearing age, pregnant and lactating women, elderly patients, and patients with underlying comorbidities.
2026-05-18 04:21:15
Olutasidenib (Rezlidhia) is an oral IDH1 mutation inhibitor developed by Rigel Pharmaceuticals. Approved by the FDA in 2022, it is used for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) harboring IDH1 mutations. With definite efficacy and good tolerability, it provides a precise targeted treatment option for such patients.
2026-05-18 04:06:05
Capmatinib, a highly selective MET inhibitor, demonstrates transformative efficacy in METex14-mutated NSCLC. Pivotal GEOMETRY data show significant tumor shrinkage and survival improvement, particularly in brain metastases. Global accessibility through originator and generic options empowers patients, while ongoing combo therapies and resistance research expand future horizons.
2026-05-15 02:34:50
Beyond its traditional TKI role, Cabozantinib is reshaping cancer care as a core agent across RCC, RAI-R DTC, HCC, and NETs. This article dissects its expanding indications, synergistic combination strategies, side effect management, and global access dynamics, offering actionable insights for patients and clinicians in the Asia-Pacific and international communities.
2026-05-12 03:08:03
Tucatinib, an oral TKI developed by Seagen, selectively targets HER2 to inhibit cancer cell growth. Approved by FDA in 2020 for advanced HER2+ breast cancer (including brain metastases) and expanded to RAS-wildtype HER2+ CRC in 2023. This treatment, combined with trastuzumab and capecitabine, significantly prolongs survival and improves outcomes. This article details indications, dosing, precautions, and safety profiles for informed clinical use.
2026-05-11 02:36:52
Pralsetinib, a highly selective RET inhibitor, is revolutionizing treatment for RET fusion-positive NSCLC and MTC. This article delves into its mechanism, clinical data, administration guidelines, and global accessibility, offering essential insights for patients and clinicians.
2026-04-30 04:14:23
This article details the mechanism of action, precise indications, eligible patient populations, and clinical value of elacestrant, analyzing its unique advantages and application boundaries in the treatment of endocrine-resistant hormone receptor-positive breast cancer.
